(1) HCV is the leading cause of liver cancer, transplantation, and liver-related mortality worldwide, with numbers projected to increase until 2030.
C hronic hepatitis C virus (HCV) infection is a global epidemic affecting approximately 71 million people. (1) HCV is the leading cause of liver cancer, transplantation, and liver-related mortality worldwide, with numbers projected to increase until 2030. (2) 
Abbreviations: AE, adverse event; AUC 24h , area under the curve at 24 hours; BMI, body mass index; DAA, direct-acting antiviral; ECG, electrocardiogram; EF, ejection fraction; EOT, end of treatment; GT, genotype; HCV, hepatitis C virus; LLOQ, lower limit of quantification; NGS, next-generation sequencing; ODV, odalasvir; PegIFN, pegylated interferon; QD, once daily; QOD, every other day; R AS, resistanceassociated substitution; SMV, simeprevir; SVR12/24, sustained virologic response 12/24 weeks after the end of treatment; and TEAE, treatmentemergent adverse event.
Many direct-acting antiviral agents (DAAs) are being evaluated, and 2-DAA and 3-DAA regimens increase viral suppression, prevent emerging resistance, and remove the need for co-administration with interferon. Such treatment options are indicated for 8-24 weeks of treatment, depending on the HCV genotype (GT) and clinical characteristics (e.g., cirrhosis status and treatment history). (3) Combining DAAs with different mechanisms of action may provide additive antiviral efficacy and prevent emergence of resistance, which could result in a shorter treatment duration across all patient populations. (4) Shortening treatment duration also has the potential to improve treatment uptake, adherence, and tolerability, and thereby improve patient outcomes. (5) Although the new pangenotypic combinations of sofosbuvir/velpatasvir and glecaprevir/pibrentasvir have reduced treatment duration to 8 weeks in some patient populations, (4, 6) attempts to shorten treatment duration to fewer than 8 weeks have generally resulted in high viral relapse rates. (7) (8) (9) AL-335, odalasvir, and simeprevir are DAAs with different mechanisms of action. AL-335 is a pro-drug of a uridine-based nucleoside polymerase (NS5B) inhibitor that has potent antiviral activity against HCV GT1-GT6. In a prior monotherapy study in healthy volunteers, AL-335 demonstrated potent antiviral activity against HCV GT1-GT4 and was well tolerated, with no identified safety signals. (10) Odalasvir is an investigational HCV NS5A inhibitor with potent in vitro antiviral activity against HCV GT1, GT2, GT4, GT5 and GT6, (11) and reduced activity against HCV GT3 (data on file). Reversible cardiac effects (cardiac hypertrophy, dilatation, reduced contractility, and prolonged conduction times) have been observed in nonclinical studies in dogs and rats at exposures 10-100 times higher than those used in clinical studies (data on file). Changes in electrocardiograms (ECGs), such as Mobitz Type 1 second-degree atrioventricular block (Wenckebach) and PR prolongation, but no changes in cardiac muscle mass (as assessed by echocardiogram) have been observed in prior clinical studies involving odalasvir (data on file).
Simeprevir is an HCV NS3/4A protease inhibitor with potent antiviral activity against HCV GT1, GT2, GT4, GT5 and GT 6, and is approved in combination with sofosbuvir for HCV GT1 and four infections. The most common adverse events (AEs) associated with simeprevir in combination with sofosbuvir include mild headache, fatigue, and nausea, and when given in combination with pegylated interferon (pegIFN) and ribavirin, were rash (including photosensitivity) pruritus, nausea, and increased bilirubin. (12) A phase I study (AL-335-602; NCT02512562) previously evaluated the pharmacokinetics of these three drugs in healthy volunteers. This study observed much higher exposures for AL-335, and mild increases in simeprevir and odalasvir when co-administered. (13) Here, we describe available results for the phase IIa, open-label study AL-335-604 (NCT02569710), which evaluated the safety, pharmacokinetics, and efficacy of an oral regimen of AL-335 + odalasvir ± simeprevir for 6-12 weeks in treatment-naïve, HCV genotype GT1-infected and GT3-infected patients, without compensated cirrhosis.
Patients and Methods
This study evaluated the safety, tolerability, efficacy, and pharmacokinetics of 3-DAA and 2-DAA regimens in treatment-naïve, HCV GT1/3-infected patients without cirrhosis, and in treatment-naïve/ aRtICle INFoRMatIoN: pegIFN-experienced GT1/2-infected patients with compensated Child-Pugh class A cirrhosis. Study conduct is ongoing for patients with cirrhosis; therefore, this manuscript presents information for patients without cirrhosis only, all of whom have completed the study. Further details can be found in the study protocol (Supporting Information).
StUDy oBJeCtIVeS
The primary objective of this study was to evaluate the safety and tolerability of short-duration AL-335 + odalasvir ± simeprevir in patients with HCV GT1/3 infection, without cirrhosis.
Secondary objectives included evaluation of efficacy: (1) patients achieving sustained virologic response (SVR) (HCV-RNA levels less than the lower limit of quantification [LLOQ] detectable or undetectable) at 4 weeks, 8 weeks, 12 weeks, 18 weeks, and 24 weeks after the end of treatment (EOT); (2) the rates of viral relapse after treatment (patients not achieving SVR12 and with undetectable HCV-RNA at EOT and confirmed HCV-RNA ≥ LLOQ during follow-up); (3) rates of on-treatment failure (patients not achieving SVR12 with confirmed detectable HCV-RNA at EOT); and (4) HCV-RNA viral kinetics (proportion of patients with HCV-RNA undetectable and HCV-RNA < LLOQ at specified time points).
Further secondary objectives included the analysis of viral resistance in those not achieving SVR; the effect of baseline NS3, NS5A, or NS5B polymorphisms on treatment outcome; the effect of baseline characteristics on treatment outcome; and the pharmacokinetic profile of AL-335 (and metabolites ALS-022399 and ALS-022227), odalasvir, and simeprevir.
StUDy DeSIgN aND tReatMeNt
This was a phase IIa, open-label study consisting of a 50-day screening period, up to a 12-week treatment period, and 24-week follow-up period. The study was conducted at two sites in New Zealand.
The initial patient population (treatment-naïve, GT1-infected subjects without cirrhosis) and treatment regimen (AL-335 400 mg once-daily [QD] + odalasvir 50 mg QD + simeprevir 100 mg QD for 8 weeks) to be evaluated in cohort 1 were predefined based on the results from study AL-335-602 in healthy volunteers, (13) available pharmacodynamic data from the AL-335 monotherapy study AL-335-601 (NCT02339207), (10) the phase IIa odalasvir/sofosbuvir study (ACH102-017), (14) and simeprevir phase II/III studies (NCT00882908; NCT01567735). (15, 16) Populations and regimens to be evaluated in subsequent cohorts were determined based on emerging data. Any of the following parameters could be modified as long as they remained within predefined ranges: (1) treatment duration: 4-12 weeks (treatment could be extended to 12 weeks if emerging data suggested inadequate efficacy); (2) doses of study drug: AL-335 400-800 mg QD, odalasvir 25-50 mg QD or every other day (QOD), and simeprevir 75-150 mg QD (if included); (3) GT: 1, 2, or 3; and (4) cohort size: 10-20 patients.
Patients were instructed to take AL-335 + odalasvir ± simeprevir with food (or up to 15 minutes after a meal) at approximately the same time QD or QOD (odalasvir only).
The futility of the regimens was assessed by the sponsor based on predefined criteria. If viral breakthrough or inadequate virologic response occurred in more than 2 patients in a cohort while recruitment was ongoing, or viral relapse occurred during the follow-up phase in approximately 15% of patients in a cohort, appropriate action was taken. This could include stopping the enrollment of treatment arms and/or extending treatment duration.
patIeNtS
The key inclusion criteria for patients required that they were 18-70 years of age with a body mass index (BMI) of 18-35 kg/m 2 and documented HCV GT1, GT2, or GT3 infection for at least 6 months, without evidence of cirrhosis. Patients had to have an HCV-RNA plasma level greater than or equal to 50,000 IU/mL, be treatment-naïve (no prior exposure to any approved or investigational drugs including DAAs and interferon-based treatment regimens) and have a FibroScan result of less than or equal to 12.5 kPa within 6 months of the baseline visit.
The key exclusion criteria included clinically significant comorbidities; a positive test for hepatitis A virus immunoglobulin M, hepatitis B surface antigen, or HIV antibody; evidence of hepatic decompensation; history or evidence of significant cardiac findings, including evidence of cardiac disease; screening echocardiogram ejection fraction (EF) less than 55%; or abnormal ECG findings. Exclusionary laboratory abnormalities included platelet count less than or equal to 120 × 10 9 /L and alanine aminotransferase greater than or equal to 5-times the upper limit of normal.
Concomitant use of potent and moderate CYP3A4 inducers/inhibitors, P-glycoprotein inhibitors, and CYP3A substrates with a narrow therapeutic index was not permitted. Consumption of grapefruit, grapefruit juice, and Seville oranges was also prohibited throughout the study until follow-up week 4.
StUDy aSSeSSMeNtS

Safety
Safety and tolerability were evaluated throughout, by the assessment of treatment-emergent AEs (TEAEs), analysis of blood and urine samples (e.g., hematology, chemistry, urinalysis), ECGs, echocardiograms, vital signs, and physical examination. AEs were evaluated/documented using the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (November 2014). (17) Twelve-lead ECGs were obtained in triplicate at prespecified time points and echocardiograms were performed at regular intervals. Mean values of ECG results were used for interpretation. In addition to being reviewed locally, ECGs and echocardiograms were submitted for central review by a single expert cardiologist, whose interpretations are summarized.
efficacy
Blood samples for determination of HCV-RNA levels were taken at screening, baseline (predose), days 2, 3, weekly on-treatment, EOT, and at follow-up weeks 4, 8, 12, 18, and 24. Blood samples were processed centrally in real time using an in vitro nucleic acid amplification test (COBAS AmpliPrep/COBAS TaqMan HCV Test, version 2.0 [Roche Molecular Diagnostics, Pleasanton, CA]) for the quantification of HCV-RNA in human plasma (LLOQ of 15 IU/mL). (18) A blood sample was taken at screening for HCV genotyping using the Abbott HCV Genotype II assay (Abbott Molecular, Des Plaines, IL). In addition, at baseline an HCV geno/subtyping assay, based on Sanger sequencing of a 336-basepair NS5B fragment followed by basic local alignment search tool analysis and/or phylogenetic analysis (DDL Diagnostic Laboratory, Rijswijk, Netherlands), was performed.
Samples for viral sequencing of the HCV NS3/4A, NS5A, and NS5B regions were collected at baseline and postbaseline at the same time points as those for HCV-RNA quantification, to identify pre-existing sequence polymorphisms and to characterize the potential for the emergence of viral resistance to AL-335, odalasvir, and/or simeprevir in patients who did not achieve SVR. Sanger population sequencing was performed and, in addition, next-generation sequencing (NGS) using a 1% read frequency cut-off in selected samples. For NS5A and NS5B, the resistance analyses considered lists of amino acid positions of interest that are associated with resistance to NS5A or NS5B inhibitors, including positions of specific interest for odalasvir or AL-335 based on in vitro or clinical observations. (19, 20) For NS3, the analyses focused on known simeprevir resistance-associated substitutions (RASs). (12, 21) pharmacokinetics Blood samples for plasma pharmacokinetics were obtained at a single time point before dosing at all routine study visits while patients were receiving study medication, and at 2-4 hours postdose at weeks 3 and 6, and at 6-8 hours postdose at weeks 4 and 8, as appropriate.
Additional pharmacokinetic blood samples for plasma drug concentrations were also obtained at week 2 in a subgroup of patients who consented to intensive pharmacokinetic sampling at this time point (intensive pharmacokinetic subset). Blood samples were taken predose, 0.5, 1, 2, 3, 4, 6, 9, 12, and 24 hours postdose.
Plasma concentrations of AL-335 (and metabolites), odalasvir, and simeprevir were determined using validated liquid chromatography-tandem mass spectrometry. The LLOQ was 1 ng/mL, 2 ng/mL, and 5 ng/mL for AL-335, ALS-022399, and ALS-022227, respectively (inVentiv Health, Somerset, NJ), 1 ng/mL for odalasvir (PRA Health Sciences, Lenexa, KS), and 2 ng/mL for simeprevir (PRA Health Sciences, Assen, Netherlands).
Statistical analyses
As this was a phase IIa exploratory study, no formal sample-size calculation was performed. A total sample size of approximately 20 patients/cohort was considered sufficient to explore the preliminary safety, pharmacokinetics, and efficacy of the study regimens in various HCV-infected subpopulations. All patients enrolled in the study, who received at least one dose of any study drug, were included in the safety and efficacy populations.
Safety data including TEAEs, clinical laboratory tests, vital signs, ECGs, echocardiography, and physical examinations were analyzed using descriptive statistical methods. TEAEs were coded using the Medical Dictionary for Regulatory Activities (version 18) and incidence rates were calculated.
SVR rates were calculated along with ClopperPearson 95% confidence intervals. Pretreatment HCV NS3/4A, NS5A, and NS5B polymorphisms, and relevant changes in the HCV NS3/4A, NS5A, and NS5B regions in patients not achieving SVR, were also analyzed descriptively.
Cohorts with the same patient population and treatment regimen at baseline were pooled.
Noncompartmental analysis of AL-335 (and metabolites), odalasvir, and simeprevir in the intensive pharmacokinetic subset was done using Phoenix WinNonlin 6.4 (Certara, Princeton, NJ) and pharmacokinetic parameters summarized using descriptive statistics. In addition, a three-compartmental model with lagged dual first-order absorption and first-order elimination was used to simulate different dosing regimens, with and without the co-administration of simeprevir, (22) to help determine a dose of odalasvir that matched the observed odalasvir exposures from a previous study (ACH102-017). (14) ethics approval
The study was conducted in accordance with the International Conference on Harmonization, Good Clinical Practice and the Declaration of Helsinki, and all applicable national regulations governing clinical trials. The study protocol was approved by the appropriate institutional review board/independent ethics committee at each study center. All patients provided written informed consent to participate.
Results
patIeNt DISpoSItIoN aND CoHoRtS eValUateD
Patient disposition is defined in Fig. 1 . In total, 190 patients were screened and 112 patients were enrolled. One hundred and eight patients (96%) completed a full course of study treatment, and 4 (4%) patients discontinued treatment prematurely: 1 as a precautionary measure due to an entry criterion violation (baseline prolonged PR interval), 1 due to a TEAE (Mobitz type 1 second-degree atrioventricular block: Wenckebach), and 2 due to viral breakthrough (Fig. 1 ).
Patients were enrolled across six cohorts, which were identified as cohorts 1, 1b, 2, 3, 4, and 5. Cohorts 1b and 4 enrolled the same population and used the same treatment regimen and therefore were combined for analysis (cohort 1b+4). The specific populations and treatment regimens evaluated are presented in Fig. 2 . These selections enabled the assessment of safety, pharmacokinetics, and efficacy of (1) an 8-week 3-DAA regimen (cohort 1) versus 8-week (extended to 12-week) 2-DAA regimen (cohorts 1b+4) in GT1-infected patients; (2) 8-week (cohort 2) versus 6-week (cohort 3) treatment durations of a 3-DAA regimen in GT1-infected patients; and (3) an 8-week (extended to 12-week) 3-DAA regimen in GT3-infected patients (cohort 5).
Patient demographic and baseline disease characteristics by cohort are detailed in Table 1 
SaFety
Overall, 87 of 112 patients (78%) reported experiencing any TEAEs, which are summarized in Table 2 . Among these, 3 were considered serious TEAEs, 1 of which was considered possibly related to odalasvir (Mobitz type 1 second-degree atrioventricular block [Wenckebach] ). This event occurred in a female GT1a-infected patient, 62 years of age, in cohort 1 and was not associated with clinical or echocardiographic abnormalities and resolved after discontinuation of study drugs. The odalasvir plasma trough concentrations for this patient were the second highest odalasvir concentrations observed in cohort 1 at Weeks 2 and 3. The week-6 odalasvir plasma concentrations at trough was 639 ng/mL (Fig. 3) . The other 2 serious TEAEs (bladder cancer and cellulitis in 2 patients in cohort 1b+4) were considered unrelated to the study drugs. No other TEAEs resulted in premature discontinuation of study drugs and no grade-3/4 TEAEs were reported in any of the cohorts. The most commonly reported (defined as more than 6 patients) TEAEs were headache (25 patients), fatigue (21 patients), upper respiratory tract infection (18 patients), and back pain (7 patients).
With regard to cardiac assessments, other than the Wenckebach case, no other treatment-emergent ECG findings triggered discontinuation or additional therapies. Similarly, no treatment-emergent EF decrease greater than 10% or EF less than 55%, or clinically significantly abnormal overall interpretation was observed in any cohort.
The following treatment-emergent grade 3/4 biochemistry/urinalysis abnormalities were observed: high cholesterol (n = 1 in cohort 2), high triglycerides (n = 2 in cohort 1b+4), high lipase (n = 1 in cohort 1, n = 2 in cohort 1b+4, and n = 1 in cohort 2), high creatinine (n = 1 in cohort 4), low phosphate (n = 3 in cohort 5), high creatine kinase (n = 1 in cohort 2), high prothrombin international normalized ratio 
eFFICaCy
Efficacy results are presented in Fig. 4 .
three-Daa Versus 2-Daa (gt1; 8-Week treatment Duration)
In cohort 1, 20 of 20 (100%) GT1-infected patients receiving a 3-DAA regimen (AL-335 400 mg QD, odalasvir 50 mg QD, and simeprevir 100 mg QD) for 8 weeks achieved SVR12 and SVR24. In cohort 1b+4, 21 of 25 (84%) patients receiving a 2-DAA regimen (AL-335 800 mg QD and odalasvir 50 mg QOD) for 8 weeks achieved SVR12. Because this SVR rate was considered unacceptable (i.e., < 90%) relative to commercially available HCV DAA regimens, the remaining 8 patients in cohort 4 who were still receiving treatment at the time these data became available had their treatment extended to 12 weeks, and 7 of 8 (88%) achieved SVR12. Overall, in cohort 4 and cohort 1b+4, 10 of 13 (77%) and 28 of 33 (85%) patients, respectively, achieved SVR12 regardless of treatment duration. Among the 5 patients with HCV GT1 who experienced virologic failure in cohort 1b+4, 4 experienced viral relapse after completing 8 weeks of treatment, and 1 developed virologic breakthrough during 12 weeks of treatment (Fig. 4A) .
eight-Week Versus 6-Week treatment Duration (gt1; 3-Daa)
In cohorts 2 and 3, 20 of 20 (100%) GT1-infected patients receiving AL-335 800 mg QD, odalasvir 50 mg QOD, and simeprevir 75 mg QD for 8 or 6 weeks, respectively, achieved SVR12 (Fig. 4B ).
3-Daa (8-Week treatment Duration) in gt3-Infected patients
In cohort 5, none of the first 5 GT3-infected patients enrolled achieved SVR12 after 8 weeks of treatment, as 100% (5 of 5) of patients relapsed after completing therapy. The remaining patients (n = 14) who were still receiving their assigned dosing regimen at the time these data became available had their treatment duration extended to 12 weeks. Of these, 10 of 14 (71%) achieved SVR12, with 2 of 14 (14%) patients experiencing viral relapse and 1 of 14 (7%) experiencing viral breakthrough (Fig. 4C) . One patient was lost to follow-up after the EOT visit.
All patients achieving SVR12 in cohorts 1-5 also achieved SVR24.
FIg. 4.
Rate of SVR12 and reasons for failure according to treatment regimen and patient GT: 3-DAA versus 2-DAA in GT1-infected patients (cohorts 1 and 1b+4) (A); 3-DAA 8-week versus 6-week regimen in GT1-infected patients (cohorts 2 and 3) (B); 3-DAA regimen in GT3-infected patients (cohort 5) (C). *One of 14 (7%) patients was lost to follow-up after the EOT visit. All patients achieving SVR12 also achieved SVR24. Abbreviations: CI, confidence interval; VBT, viral breakthrough.
Viral Resistance BaSelINe NS3 polyMoRpHISMS
Overall, 3 of 59 (5%) GT1-infected patients treated with 3-DAA and with NS3 sequencing data available, had a baseline NS3 Q80K polymorphism: 2 of 50 (4%) GT1a-infected patients and 1 of 9 (11%) GT1b-infected patients. An additional 2 of 59 (3%) GT1-infected patients had baseline simeprevir RASs other than Q80K (R155K and D168E, respectively). The 5 patients with baseline NS3 simeprevir RASs received 8 weeks of 3-DAA treatment, and all of these patients achieved SVR12 (Supporting Fig. S1 ).
All GT3-infected patients carried the NS3 simeprevir RAS Q168 at baseline, except for 1 GT3-infected patient who had a baseline Q168K.
BaSelINe NS5a polyMoRpHISMS
Baseline polymorphisms considering NS5A positions 28, 29, 30, 31, 32, 58, 92, and 93 were present in 10 of 60 (17%) and 9 of 33 (27%) GT1-infected patients treated with the 3-DAA or the 2-DAA combination, respectively. The polymorphisms seen in 2 of these patients are associated with in vitro resistance to odalasvir (M28V + Q30R [n = 1] and Y93N [n = 1]). Both patients received the 2-DAA regimen and experienced virologic failure.
In GT3, NS5A polymorphisms were detected at baseline in 4 of 18 (22%) patients with NS5A sequence data available, and all of these were associated with in vitro resistance to odalasvir (Y93H [n = 3] and A30K [n = 1]). Two of these 4 patients achieved SVR12 (Supporting Fig. S1 ). Of those not achieving SVR12, 1 experienced viral breakthrough and 1 experienced viral relapse.
BaSelINe NS5B polyMoRpHISMS
No patients had the AL-335 NS5B RAS S282T at baseline.
tReatMeNt-eMeRgeNt RaSS
The 5 GT1a-infected patients who failed treatment with the 2-DAA regimen had emerging NS5A and/or NS5B RASs at time of failure (Table 3 ). In the 4 patients with emerging NS5A RASs, these RASs were still detectable at end of study (by Sanger population sequencing and/or NGS if available; follow-up time of 12-20 weeks). Emerging NS5B S282T was detected at time of failure in 2 of these patients and was no longer detected by NGS at a read frequency greater than or equal to 1% at end of study in 1 of 2 patients (follow-up time of 21 and 20 weeks, respectively). In the 1 patient with S282T still detectable by NGS at end of study, the S282T variant was detected as the dominant viral variant with an NGS read frequency of 98%.
Six of 8 GT3-infected patients who failed treatment had emerging NS5B S282T at time of failure. At the end of the study, emerging NS5B S282T was no longer detectable in these 6 patients by NGS at a read frequency of greater than or equal to 1% (follow-up time of 20-24 weeks).
pharmacokinetics
The pharmacokinetics of AL-335, odalasvir, and simeprevir in the pharmacokinetic substudy are summarized in Supporting Table S1 ). In the pharmacokinetic substudy, increasing the AL-335 dose from 400 to 800 mg QD in the presence of reduced odalasvir (50 mg QD to 50 mg QOD) and simeprevir (100 to 75 mg QD) doses had little effect on ALS-022227, which increased less than dose proportionally. Reducing the odalasvir dose resulted in a proportional decrease in odalasvir exposure and decreasing the simeprevir dose from 100 to 75 mg QD (in the setting of half the initial dose of odalasvir) decreased simeprevir area under the curve at 24 hours (AUC 24h ) less than dose proportionally.
In the main study (Fig. 3) , increasing the dose of AL-335 from 400 mg to 800 mg increased ALS-022227 trough concentrations, which increased further with the addition of simeprevir. Reducing the dose of simeprevir (from 100 mg to 75 mg) or odalasvir (from 50 mg QD to QOD) decreased simeprevir and odalasvir trough concentrations, respectively. Odalasvir exposure increased with the addition of simeprevir. To further refine the dose of odalasvir, modeling and simulation was carried out to achieve an efficacious exposure and reduce toxicity, while accounting for food effect, change in formulation (liquid-filled capsules in previous studies to tablets in this study), and interaction with simeprevir (data not shown), from which the optimal dose of odalasvir was determined to be 25 mg QD. (22) gaNe et al.
Hepatology, December 2018
2154
Discussion
In this phase IIa clinical study, treatment regimens involving AL-335, odalasvir, and simeprevir were assessed for their safety, pharmacokinetics, and efficacy in multiple HCV-infected patient populations.
With respect to safety, all reported TEAEs were mild to moderate in severity, and serious TEAEs were uncommon with three events reported. Of these, one event was considered of clinical significance and possibly related to odalasvir. This case, Mobitz type 1 second-degree atrioventricular block (Wenckebach) S282T not observed by NGS at a read frequency greater than or equal to 1%. occurred in cohort 1 and was considered possibly odalasvir-related for the following reasons: (1) this same event was seen in other clinical/nonclinical studies involving odalasvir but has not been observed in prior studies of simeprevir or AL-335; (2) it occurred in the cohort in which odalasvir exposures were approximately twice higher (cohort 1, mean AUC 24h 11,798 ng.h/mL versus 5022 and 6197 ng.h/mL in cohorts 2 and 3, respectively); and (3) no additional cases of PR prolongation requiring discontinuation of study drug occurred following reduction in odalasvir dose in cohorts 2-5. All other safety parameters including TEAEs, laboratory abnormalities, ECGs, echocardiograms, physical examinations, and vital signs were without any clinically concerning findings. Thus, from a safety perspective, the 2-DAA and 3-DAA regimens evaluated appear to be well tolerated for durations up to 12 weeks, particularly when odalasvir is dosed at 50 mg QOD. The 100% SVR12/24 efficacy rates achieved in GT1-infected, treatment-naïve patients without cirrhosis with the 3-DAA combinations is higher than observed previously with such short treatment durations. (7) (8) (9) Indeed, such a high efficacy rate after 6 weeks of treatment has only been previously reported with one other DAA combination, which also contained odalasvir. (14) The results, although based on relatively small sample sizes, are promising enough relative to the current standard-of-care regimens (3) and help justify further evaluation of an AL-335 800 mg QD + odalasvir 25 mg QD + simeprevir 75 mg QD ( JNJ-4178) regimen over a 6-week to 8-week treatment duration in this population. To this end, a large, phase IIb study of this regimen in GT1-, GT2-, GT4-, GT5-, or GT6-infected patients without cirrhosis (OMEGA-1; NCT02765490) has recently been completed.
Notably, the presence of NS5A polymorphisms at baseline did not affect the efficacy of the 3-DAA combination in GT1-infected patients. High SVR12 rates were achieved with 6 and 8 weeks of 3-DAA treatment in GT1-infected patients, regardless of the presence of baseline NS5A polymorphisms and/or simeprevir RASs, including NS3 Q80K.
In this study, reduced efficacy was observed with the 2-DAA combination in GT1-infected patients, and inadequate efficacy was observed with the 3-DAA combination in GT3-infected patients. On the basis of these data, it was determined that the 2-DAA combination would not be further evaluated in HCVinfected patients, and the 3-DAA combination would not be further evaluated in patients with GT3 infection. In most of these patients, emerging RASs in NS5A and/or NS5B were detected at time of failure. The finding of emerging resistance to a nucleotide analog NS5B inhibitor was related to failure in regimens/populations with suboptimal efficacy, and this has also been described for other 2-/3-DAA regimens with reduced efficacy. (23) Nevertheless, in a much larger global phase IIb study (OMEGA-1) of this same 3-DAA combination, NS5B resistance was not observed following treatment failure. (24) Equally important, for all but one of the cases of emerging NS5B resistance observed in this current study, the RAS had become undetectable by at least the last study visit (SVR24 visit), presumably because this was less fit than wild-type virus. Emerging NS5A RASs remained detectable at the end of the study, which is in line with previous observations for the long-term persistence of emerging NS5A RASs. (25) Several factors may contribute to the reduced efficacy of this 3-DAA regimen in GT3-infected patients. First, simeprevir has limited antiviral activity against HCV GT3, which can be explained by the presence of a naturally occurring Q168 polymorphism in the NS3 protease of HCV GT3, which confers high-level resistance to simeprevir. (26, 27) In addition, emerging data from in vitro experiments using a GT3 chimeric replicon (carrying full-length NS5A of GT3 in a GT1b replicon backbone) showed reduced activity of odalasvir against GT3 compared with GT1. Additionally, HCV GT3 has consistently been shown to be more difficult to cure across a range of studies of DAA treatment. (28) The initial dose of odalasvir was reduced from 50 mg QD in cohort 1 to the equivalent of 25 mg QD in all cohorts after cohort 1. This was done in response to emerging pharmacokinetic results and to reduce the interaction with simeprevir and minimize the risk of odalasvir-related toxicity (e.g., PR prolongation) associated with higher exposures. However, due to the formulation of odalasvir at the time (i.e., 50-mg unscored tablets), patients were dosed with 50 mg QOD in this study. As projected, this approximately 50% reduction in frequency resulted in a corresponding approximately 50% reduction in odalasvir exposures. Compared with cohort 1, in which odalasvir 50 mg QD was given, the lower odalasvir 50 mg QOD dose continued to provide robust efficacy in GT1-infected patients despite the lower exposures and was not associated with any PR prolongations that required discontinuation of study drugs.
ALS-022227 exposures observed in this study at 400 mg QD (cohort 1) in combination with odalasvir/simeprevir were comparable to the same dose under monotherapy despite higher AL-335 exposures. Therefore, the AL-335 dose was increased to a dose previously found to be highly efficacious when given as monotherapy (800 mg QD) in subsequent treatment groups to maximize antiviral efficacy. (10) Although simeprevir exposure was increased by 1.7-fold when administered in combination with odalasvir, compared with simeprevir administered alone in a healthy volunteer drug-drug interaction study, results from cohort 1 indicated that there is no significant interaction in HCV-infected patients. The difference in interaction effect may be related to the effect of liver disease on hepatic transporters. (29) In the phase IIb PILLAR study of simeprevir in combination with pegIFN and ribavirin, simeprevir doses of 75 and 150 mg QD were evaluated in treatment-naïve, HCV-infected patients, and no significant difference in SVR rates was observed, only a trend for higher SVR with the higher dose in some difficult-to-cure subpopulations. (15) However, in the context of an interferon-free 3-DAA regimen in which simeprevir is administered in combination with two other potent DAAs, it was hypothesized that 75 mg QD would provide optimal efficacy when administered along with AL-335 and odalasvir. In addition, simeprevir at a lower 75-mg QD dose is expected to be associated with a lower frequency of TEAEs. Furthermore, the potential risk of higher exposures of odalasvir due to drug interactions with simeprevir was anticipated to be lower when simeprevir is administered at a lower dose. Therefore, the simeprevir dose was reduced from 100 to 75 mg QD after cohort 1.
The efficacy and pharmacokinetic results from the current study provided the rationale for the doses of AL-335, odalasvir, and simeprevir selected for the OMEGA-1 phase IIb study.
The strengths of the AL-335-604 study included the flexible study design, which enabled multiple key questions for therapy selection for the phase IIb study to be preliminarily assessed. These included 3-DAA versus 2-DAA for GT1 infection, 3-DAA 8 weeks versus 6 weeks for GT1 infection, and 3-DAA for GT3 infection. Limitations of the study included the open-label nature, the limited sample size, and the lack of a comparator group.
In conclusion, the 3-DAA regimen of AL-335, odalasvir, and simeprevir for 6 or 8 weeks was highly efficacious in GT1-infected patients without cirrhosis, and was generally safe and well tolerated, with predictable pharmacokinetics. However, the observed efficacy of this 3-DAA regimen in GT3-infected patients and the 2-DAA regimen in GT1-infected patients, without cirrhosis, was inadequate to justify further evaluation in phase IIb. Furthermore, in light of the recent availability of highly effective pangenotypic regimens, the decision was taken to cease further development of this 3-DAA regimen.
